Press Releases

Dyadic to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018

JUPITER, FL – October 24, 2018 (ACCESSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will report its financial results for the quarter…

Dyadic Announces Analyst Coverage Initiated by Zacks Small-Cap Research

JUPITER, FL – October 16, 2018 GLOBE NEWSWIRE Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, today announced that Zacks Small-Cap Research (“Zacks SCR”) has initiated analyst…

Dyadic International Announces Research Collaboration with Sanofi-Aventis

JUPITER, FL – September 7, 2018 (GLOBE NEWSWIRE) Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a fully funded proof…

Dyadic Reports 2Q2018 Financial Results and Extension of Stock Repurchase Program

JUPITER, FL – August 9, 2018 (GLOBE NEWSWIRE) Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, announced its financial results for the second quarter and six months ended…

DYADIC INTERNATIONAL TO ANNOUNCE SECOND QUARTER 2018 FINANCIALS AND HOST CONFERENCE CALL

JUPITER, FL – July 26, 2018 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…

Dyadic International Improves Monoclonal Antibody (mAb) Productivity Utilizing C1 Gene Expression Platform to Manufacture Biologics

Results Highlighted in BioProcess International and the Global Bioprocessing and Bioanalytics Congress 2018 
JUPITER, FL – June 18, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales,…

DYADIC INTERNATIONAL REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

Three new research collaborations
Positive results in our initial glycoengineering modifications of C1 strains
Achieving high levels of productivity for therapeutic proteins
Board approved a reverse stock split subject to shareholder approval
Recognized industry thought leader joins board
New Chief Accounting Officer appointed
$47.7 million of cash, cash equivalents and investment securities at March 31, 2018

 JUPITER, FL -…

DYADIC INTERNATIONAL TO ANNOUNCE FIRST QUARTER 2018 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON THURSDAY MAY 10, 2018

JUPITER, FL – April 25, 2018 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…

Dyadic Reports 4Q2017 Financial Results

Dyadic International Announces 2017 Year End Results and Recent Developments

$49.1 million of cash, cash equivalents and investment securities as of December 31, 2017
Successfully executed two funded collaborations in 2017 and signed three new collaborations in 2018
Early data generated from our research programs are showing encouraging results for C1 technology
Settlement with the last remaining defendant in…

Dyadic International Appoints Chief Accounting Officer

JUPITER, FL – March 15, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), today announced that Chief Financial Officer Thomas L. Dubinski 
will be on a medical leave of absence, effectively immediately. In Mr. Dubinski’s absence, other executive officers will assume many of Mr. Dubinski’s duties while remaining in their current positions. Ping W. Rawson, the Company’s…

DYADIC INTERNATIONAL TO ANNOUNCE YEAR END 2017 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON TUESDAY MARCH 27, 2018

JUPITER, FL – March 13, 2018 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the year…

Dyadic International, Inc. Announces Research and Development Collaboration with Mitsubishi Tanabe Pharma Corporation To Produce Two Target Proteins in C1

JUPITER, FL – February 27, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic products at commercial scales, today announced that it has entered into a funded proof of concept research collaboration to…

Dyadic International, Inc. Announces Research and Development Collaboration To Produce An Active Ingredient in C1

JUPITER, FL – February 7, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic products at commercial scales, today announced that it has entered into a funded proof of concept research collaboration to…

Dyadic International, Inc. Announces New R&D Agreement

Dyadic International, Inc. Announces Research and Development Collaboration with the Israel Institute for Biological Research (IIBR) to Combat Emerging Diseases & Threats

JUPITER, FL – January 16, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production…

DYADIC INTERNATIONAL APPOINTS NEW BOARD MEMBER

JUPITER, FL – January 3, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on the development and large-scale manufacture of low cost, better performing biologic vaccines and drugs at flexible commercial scales, today announced the appointment of Barry Buckland, Ph.D., to its Board of Directors, effective January 3rd, 2018.

Dr. Buckland spent 29…

DYADIC INTERNATIONAL REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS

JUPITER, FL – November 9, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended September 30, 2017.

BUSINESS HIGHLIGHTS AND…

DYADIC INTERNATIONAL TO ANNOUNCE THIRD QUARTER 2017 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON THURSDAY NOVEMBER 9, 2017

JUPITER, FL – October 26, 2017 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…

Dyadic International Presentation Now Available for On-Demand Viewing

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation

JUPITER, Fla. October 9, 2017, /PRNewswire/ — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales,…

Dyadic Announces $5 Million Stock Repurchase Program

JUPITER, FL – August 16, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (OTCQX: DYAI) (“Dyadic”) announced that its Board of Directors has authorized a new stock repurchase program, under which the Company may repurchase up to $5 million of its outstanding common stock.

Under this new stock repurchase program, Dyadic may repurchase shares in accordance with all applicable securities laws…

DYADIC INTERNATIONAL REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS

JUPITER, FL – August 10, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended June 30, 2017.

BUSINESS HIGHLIGHTS AND RECENT…

DYADIC ANNOUNCES THE CONCLUSION OF ITS RESEARCH SERVICES AGREEMENT WITH DUPONT

JUPITER, FL – August 4, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), announced today the conclusion of formal collaborative research with Danisco US Inc., a unit of DuPont Industrial Biosciences (“Danisco”). The research collaboration was part of the previously announced DuPont Sale Transaction. The research services by Danisco will conclude September 30, 2017.

“We are grateful for…

DYADIC INTERNATIONAL TO ANNOUNCE SECOND QUARTER 2017 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON THURSDAY AUGUST 10, 2017

JUPITER, FL – July 27, 2017 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…

DYADIC ANNOUNCES AN IMPORTANT MULTI-YEAR RESEARCH AND DEVELOPMENT ARRANGEMENT TO FURTHER ADVANCE ITS PROPRIETARY C1 TECHNOLOGY

JUPITER, FL – July 10, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), announced today that it has entered into a comprehensive series of research and development agreements, including a potential commercialization agreement, with Biotechnology Development for Industry (“BDI Holdings”), a Spanish biotech company, and its subsidiaries – VLP The Vaccines Company, S.L.U. (“VLPbio”), and Biotechnology Developments…

DYADIC INTERNATIONAL ANNOUNCES $7.4M RELEASED FROM ESCROW

JUPITER, FL – July 6, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), is pleased to announce that it has received approximately $7.4 million from the escrow account established in connection with the sale of assets of Dyadic’s Industrial Technology business to DuPont on December 31, 2015.

The Company intends to use the funds to support its ongoing…

DYADIC INTERNATIONAL ANNOUNCES BOARD MEMBERS SHARE PURCHASE

JUPITER, FL – May 25, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), announced today that its Chairman of the Board, Michael P. Tarnok, and its Audit Committee Chair, Jack L. Kaye, have purchased 50,000 and 35,000 shares of Dyadic International, Inc. common stock, respectively, at $1.40 per share on Wednesday, May 24th, 2017. These shares were purchased…

Dyadic Reports 1Q17 Financial Results

JUPITER, FL – May 11, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying the proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended March 31, 2017.

BUSINESS HIGHLIGHTS AND…

Dyadic to Announce 1Q17 Financial Results and Host Conference Call

JUPITER, FL – April 27, 2017 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…

Dyadic Presents at PEGS 2017

Jupiter, FL – April 18, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI) announced that Dyadic’s Vice President of Research and Development, Dr. Ronen Tchelet, will present ”C1-The Journey of More Productive Cell Expression” at PEGS 2017, The Essential Protein Engineering Summit on Thursday, May 4, 2017 from 3:35 pm to 3:50 pm EST at the Seaport…

Dyadic Announces Director Resignation

JUPITER, FL – April 6, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (OTCQX: DYAI) (“Dyadic”), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that Stephen Warner has resigned from the Board of Directors…

DYADIC INTERNATIONAL REPORTS 2016 FINANCIAL RESULTS

JUPITER, FL – March 15, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the year ended December 31, 2016,…

DYADIC ANNOUNCES SETTLEMENT REACHED WITH LAST REMAINING LAW FIRM

Dyadic International Announces It Has Reached a Settlement With the Last Remaining Defendant Law Firm, Greenberg Traurig, LLP and Greenberg Traurig, P.A., in Its Professional Liability Litigation

JUPITER, Fla., March 2, 2017 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (OTCQX:DYAI), today announced that on March 1, 2017 it reached a confidential, mid-seven figure settlement with the last…

DYADIC TO ANNOUNCE YEAR-END 2016 FINANCIAL RESULTS AND HOST CONFERENCE CALL

JUPITER, FL – March 1, 2017 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging its patented and proprietary C1 expression system technology to help speed up the development and production of biologic drugs at flexible commercial scales, announced today that it will report its financial results for the…

Dyadic Announces Successful Completion of Stock Repurchase Program

JUPITER, FL – February 16, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (OTCQX: DYAI) (“Dyadic”), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced  the successful completion of its previously announced stock…

Dyadic International Announces the Purchase of 2.36 Million Shares of its Common Stock From Pinnacle

JUPITER, FL – January 13, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic” or the “Company”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that it entered into a…

Dyadic International Shareholders Approve Reverse Stock Split

JUPITER, FL – December 8, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic” or the “Company”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced the results of its special…

Dyadic International Reports Third Quarter 2016 Financial Results

JUPITER, FL – November 10, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended September 30, 2016.

BUSINESS…

Dyadic to Announce 3Q16 Financial Results and Host Conference Call

JUPITER, FL – October 27, 2016 (GLOBE NEWSWIRE)– Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company announced today that it will report its financial results for the third quarter ending September 30, 2016 after the market closes on Thursday, November 10, 2016 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss…

Dyadic to Seek Shareholder Approval of Reverse Stock Split

·       Special meeting to be held December 7, 2016 to seek shareholder approval
·       Proxy statement filed with the OTC Markets and posted on Dyadic’s website
JUPITER, FL – October 26, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on the development and large scale manufacture of low cost, better performing biologic vaccines and…

Dyadic Announces Research and Development Agreement to Further Advance its Proprietary C1 Fungal Strain for BioPharmaceutical Development & Production

JUPITER, FL – September 7, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on the development and large scale manufacture of low cost, better performing biologic vaccines and drugs at flexible commercial scales, today announced they have entered into a research and development agreement to further advance its proprietary C1 fungal strain…

Dyadic International, Inc. Appoints Arindam Bose, Ph.D., Distinguished Life Sciences Executive, to Board of Directors

JUPITER, FL – August 16, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on the development and large scale manufacture of low cost, better performing biologic vaccines and drugs at flexible commercial scales, today announced the appointment of Arindam Bose, Ph.D., to its Board of Directors, effective August 15, 2016.

Dr. Bose recently…

Dyadic Reports 2Q16 Financial Results

JUPITER, FL – August 11, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focusing on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended June…

Dyadic Board Approves Reverse Stock Split Subject to Shareholder Approval

JUPITER, FL – August 11, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic” or the “Company”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced the approval by its Board…

Dyadic Announces Sanofi Contract Termination

JUPITER, FL – August 8, 2016 – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI) announced today the termination of its Proof of Concept, Exclusive Option & Technology Transfer Agreement, dated, as of March 30, 2011 with Sanofi Pasteur (“Sanofi”).

On August 5, 2016, the Company received a 60-day notice from Sanofi, indicating that they have decided to terminate the Proof of…

DYADIC REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS

JUPITER, FL – May 12, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced financial results for the quarter ending March 31,…

DYADIC TO ANNOUNCE 1Q2016 FINANCIALS AND HOST CONFERENCE CALL

JUPITER, FL – April 28, 2016 (GLOBE NEWSWIRE)– Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company announced today that it will report its financial results for the first quarter ending March 31, 2016 after the market close on Thursday, May 12, 2016 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss…

DYADIC INTERNATIONAL ANNOUNCES IT HAS REACHED A SETTLEMENT WITH ONE OF THE TWO REMAINING DEFENDANT LAW FIRMS IN ITS PROFESSIONAL LIABILITY LITIGATION

JUPITER, Fla., April 6, 2016, (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), today announced it has reached a confidential settlement with one of the two remaining defendant law firms in its ongoing professional liability litigation.

A confidential settlement in a low seven figure amount was reached with the law firm of Bilzin Sumberg Baena Price & Axelrod LLP…

DYADIC INTERNATIONAL TO ANNOUNCE YEAR-END 2015 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON TUESDAY, MARCH 29, 2016

JUPITER, FL – March 15, 2016 (GLOBE NEWSWIRE)– Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company announced today that it will report its financial results for the year ending December 31, 2015 after the market close on Tuesday, March 29, 2016 and that it will host a conference call that day at 5:00 p.m. Eastern Time to…

DYADIC INTERNATIONAL, INC. ANNOUNCES A JANUARY 6, 2017 TRIAL DATE FOR LITIGATION AGAINST FORMER PROFESSIONAL SERVICES PROVIDERS

JUPITER, FL – March 3, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (OTCQX: DYAI) (“Dyadic”) announced today that in its lawsuit against Defendants Greenberg Traurig, LLP, Greenberg Traurig, P.A. (collectively, “Greenberg Traurig”) and the Estate of Robert I. Schwimmer, who previously represented the Company while an attorney at Greenberg Traurig, and also against Defendant Bilzin Sumberg Baena Price &…

DYADIC INTERNATIONAL, INC. ANNOUNCES BOARD MEMBER RESIGNATION

JUPITER, FL – January 19, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (OTCQX: DYAI) (“Dyadic”) announced today that Robert D. Burke, MD has resigned from the Board of Directors of Dyadic (the ‘Board’) and all related board committees to which he served which included the compensation, and nominating committees of the board effective January 18, 2016.

Dr. Burke has served…